

RNS Number : 2276E
Trellus Health PLC
16 September 2024



Trellus Health plc
("Trellus Health" or the "Company")

Notice of Results
Investor Presentation

LONDON, U.K. AND NEW YORK, U.S. (16 September 2024). Trellus Health plc (AIM: TRLS), a healthcare company delivering innovative, scientifically validated programs and technologies that facilitate the comprehensive management of chronic conditions, improve health outcomes and lower the costs of care, announces that it expects to report its interim results for the period ended 30 June 2024 on Thursday 26 September 2024.

Investor Presentation

Dr. Marla Dubinsky, CEO and Co-Founder, and Joy Bessenger, Chief Financial Officer, will provide a video update relating to the interim results which will be available to view on the day via the [company website](#) and the Investor Meet Company platform.

Investors can register for the Investor Meet Company Platform and receive notifications about Trellus Health plc here:

<https://www.investormeetcompany.com/trellus-health-plc/register-investor>

For further information please contact:

Trellus Health plc

Dr. Marla Dubinsky, CEO and Co-Founder
Joy Bessenger, CFO

<https://trellushealth.com/>

Via Walbrook PR

Singer Capital Markets (Nominated Adviser and Broker) Tel: +44 (0)20 7496 3000

Jen Boorer / James Todd / Jalini Kalaravy

Walbrook PR

Paul McManus / Sam Allen / Phillip Marriage

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com

Mob: +44 (0)7980 541 893 / (0)7502 558 258/ (0)7867 984 082

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services for chronic condition management that prioritises improved outcomes and member experiences while managing costs of care.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced experience that meets each individual's unique needs and empowers them to master their physical and emotional health. Trellus Elevate's™ clinically proven solutions result in relieving disease burden, building self-management skills and promoting positive health behaviours that improve outcomes and enables thriving in the face of a chronic condition.

The Company's proven whole person approach recognises the interconnectedness of various aspects of a person's life and aims to address the whole spectrum of factors that influence behaviour, to promote comprehensive well-being and human flourishing in a way that aligns with value-based care. Trellus Health's approach enables better health outcomes in a member-centric, personalised and comprehensive holistic solution.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

The Company is initially focusing on chronic costly GI conditions that have high mental health burden, such as inflammatory bowel disease ("IBD") which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis. Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

The Trellus Elevate™ program incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than seven years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers and health systems. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes¹.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

¹ Source: <https://www.sciencedirect.com/science/article/pii/S1542356521012258>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORFELFFZKLBBBX Anonymous (not verified) Notice of Results

<http://www.DigitalLook.com>

34555716 A Mon, 09/16/2024 - 07:00 LSE RNS Advance Notice of Results TRLS